EUVIMEDEUVIMED entdecken
Crossref

Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting

Kun Hu, Yijie Liu, Yizhang Liu, Lu Jian, Yongfang Duan, Ruizhen Liu, Haoqun Zhang, Junchen Chen, Mi Zhang, Yehong Kuang iD

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Kun Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Generalized pustular psoriasis (GPP) is a rare, potentially life‐threatening skin disease often requiring long‐term therapy. We aimed to evaluate the use of Interleukin (IL)‐17A inhibitors (secukinumab and ixekizumab) in GPP patients over 96 weeks.

Methods

We retrospectively analyzed a case series of 18 patients with GPP who received secukinumab ( n = 13) and ixekizumab ( n = 5) therapy with a 96‐week follow‐up period. The primary effectiveness analysis included determining the percentage of patients who achieved ≥90% or 100% improvement in the Generalized Pustular Psoriasis Area and Severity Index (GPPASI) score. Adherence was captured using the medication possession ratio (MPR).

Results

Using the as‐observed (AO) method, 87% and 67% of patients treated with secukinumab or ixekizumab achieved GPPASI 90 and 100 responses, respectively. At Week 96, the mean GPPASI improvements from baseline GPPASI were 96.3% (95% CI: 0.91–1.01) using the AO method. After Week 48, 14 patients tapered ( n = 8) or terminated ( n = 6) the treatment. High‐adherence therapy (MPR ≥ 80%) was significantly superior to the low‐adherence group in the rate of patients achieving a GPPASI 100 response (AO, 100% vs. 38%, P < 0.05). By Week 96, 5 (27.8%) patients had new GPP flares, and 4 (80%) were in the low‐adherence group. No new safety signals occurred.

Conclusion

IL‐17A inhibitors led to effective and sustained improvement in GPP patients, and high‐adherence therapy had long‐term positive effects on skin clearance. Given its relapsing nature, improving compliance is beneficial for long‐term clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17Antibodies, Monoclonal, HumanizedSeverity of Illness IndexDrug MonitoringHumansMaleFemaleMiddle AgedRetrospective StudiesAdultTreatment OutcomeAgedDermatologic AgentsTime Factors

Stichwörter der Autor:innen

adherenceeffectivenessgeneralized pustular psoriasisixekizumablong‐termsecukinumab

Substanzen

ixekizumabInterleukin-17secukinumabAntibodies, Monoclonal, HumanizedIL17A protein, humanDermatologic Agents

Autor:innen und Institutionen

  • The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, Hunan, China.
  • Furong Laboratory, Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, China.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha, Hunan, China.
  • Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha, Hunan, China.

ORCID-Profile: Yehong Kuang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Hu, K., Liu, Y., Liu, Y., Jian, L., Duan, Y., Liu, R., Zhang, H., Chen, J., Zhang, M., & Kuang, Y. (2024). Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting. International Journal of Dermatology. https://doi.org/10.1111/ijd.17163

Vancouver

Hu K, Liu Y, Liu Y, Jian L, Duan Y, Liu R, et al. Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting. International Journal of Dermatology. 2024. doi:10.1111/ijd.17163

BibTeX
@article{Hu2024,
  author = {Hu, Kun and Liu, Yijie and Liu, Yizhang and Jian, Lu and Duan, Yongfang and Liu, Ruizhen and Zhang, Haoqun and Chen, Junchen and Zhang, Mi and Kuang, Yehong},
  title = {Rapid and sustained resolution in generalized pustular psoriasis with IL‐17A inhibitors required high adherence: a 96‐week analysis in a real‐life setting},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17163}
}
Kostenlos starten →